Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector.
Georgievska, Biljana LU ; Kirik, Deniz LU ; Rosenblad, Carl ; Lundberg, Cecilia LU
and Björklund, Anders
LU
(2002)
In NeuroReport
13(1).
p.75-82
- Abstract
- We used a recombinant lentiviral vector (rLV) for gene delivery of GDNF to the striatum, and assessed its neuroprotective effects in the intrastriatal 6-hydroxydopamine (6-OHDA) lesion model.The level of GDNF expression obtained with the rLV-GDNF vector was dose-related and ranged between 0.9-9.3 ng/mg tissue in the transduced striatum, as determined by ELISA, and 0.2-3.0 ng/mg tissue were detected in the ipsilateral substantia nigra (SN), due to anterograde transport of the GDNF protein. GDNF expression was apparent at 4 days and maintained for > 8 months after injection. Striatal delivery of rLV-GDNF efficiently protected the nigral dopamine (DA) neurons and their projection, against the 6-OHDA lesion (65-77% of intact side).... (More)
- We used a recombinant lentiviral vector (rLV) for gene delivery of GDNF to the striatum, and assessed its neuroprotective effects in the intrastriatal 6-hydroxydopamine (6-OHDA) lesion model.The level of GDNF expression obtained with the rLV-GDNF vector was dose-related and ranged between 0.9-9.3 ng/mg tissue in the transduced striatum, as determined by ELISA, and 0.2-3.0 ng/mg tissue were detected in the ipsilateral substantia nigra (SN), due to anterograde transport of the GDNF protein. GDNF expression was apparent at 4 days and maintained for > 8 months after injection. Striatal delivery of rLV-GDNF efficiently protected the nigral dopamine (DA) neurons and their projection, against the 6-OHDA lesion (65-77% of intact side). Sprouting of the lesioned axons was observed along the nigrostriatal pathway, precisely corresponding to the areas containing anterogradely transported GDNF. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/107304
- author
- Georgievska, Biljana
LU
; Kirik, Deniz
LU
; Rosenblad, Carl
; Lundberg, Cecilia
LU
and Björklund, Anders
LU
- organization
- publishing date
- 2002
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Lentivirus : genetics, Luminescent Proteins : pharmacokinetics, Motor Activity : drug effects, Nerve Tissue Proteins : genetics, Nerve Tissue Proteins : pharmacokinetics, Nerve Tissue Proteins : therapeutic use, Neurons : drug effects, Neurons : metabolism, Neuroprotective Agents : therapeutic use, Oxidopamine : pharmacology, Parkinson Disease : pathology, Parkinson Disease : physiopathology, Parkinson Disease : therapy, Rats, Sprague-Dawley, Substantia Nigra : drug effects, Substantia Nigra : pathology, Support, Non-U.S. Gov't, Tyrosine 3-Monooxygenase : metabolism, Indicators and Reagents : pharmacokinetics, Genetic Vectors, Gene Transfer Techniques, Female, Dopamine : metabolism, Corpus Striatum : pathology, Corpus Striatum : drug effects, Animal
- in
- NeuroReport
- volume
- 13
- issue
- 1
- pages
- 75 - 82
- publisher
- Lippincott Williams & Wilkins
- external identifiers
-
- pmid:11924898
- wos:000173449000020
- scopus:0037148074
- ISSN
- 1473-558X
- language
- English
- LU publication?
- yes
- id
- effc8cf9-8704-4dc8-a679-b98f33b468bb (old id 107304)
- alternative location
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11924898&dopt=Abstract
- date added to LUP
- 2016-04-01 11:53:56
- date last changed
- 2022-01-26 19:53:51
@article{effc8cf9-8704-4dc8-a679-b98f33b468bb,
abstract = {{We used a recombinant lentiviral vector (rLV) for gene delivery of GDNF to the striatum, and assessed its neuroprotective effects in the intrastriatal 6-hydroxydopamine (6-OHDA) lesion model.The level of GDNF expression obtained with the rLV-GDNF vector was dose-related and ranged between 0.9-9.3 ng/mg tissue in the transduced striatum, as determined by ELISA, and 0.2-3.0 ng/mg tissue were detected in the ipsilateral substantia nigra (SN), due to anterograde transport of the GDNF protein. GDNF expression was apparent at 4 days and maintained for > 8 months after injection. Striatal delivery of rLV-GDNF efficiently protected the nigral dopamine (DA) neurons and their projection, against the 6-OHDA lesion (65-77% of intact side). Sprouting of the lesioned axons was observed along the nigrostriatal pathway, precisely corresponding to the areas containing anterogradely transported GDNF.}},
author = {{Georgievska, Biljana and Kirik, Deniz and Rosenblad, Carl and Lundberg, Cecilia and Björklund, Anders}},
issn = {{1473-558X}},
keywords = {{Lentivirus : genetics; Luminescent Proteins : pharmacokinetics; Motor Activity : drug effects; Nerve Tissue Proteins : genetics; Nerve Tissue Proteins : pharmacokinetics; Nerve Tissue Proteins : therapeutic use; Neurons : drug effects; Neurons : metabolism; Neuroprotective Agents : therapeutic use; Oxidopamine : pharmacology; Parkinson Disease : pathology; Parkinson Disease : physiopathology; Parkinson Disease : therapy; Rats; Sprague-Dawley; Substantia Nigra : drug effects; Substantia Nigra : pathology; Support; Non-U.S. Gov't; Tyrosine 3-Monooxygenase : metabolism; Indicators and Reagents : pharmacokinetics; Genetic Vectors; Gene Transfer Techniques; Female; Dopamine : metabolism; Corpus Striatum : pathology; Corpus Striatum : drug effects; Animal}},
language = {{eng}},
number = {{1}},
pages = {{75--82}},
publisher = {{Lippincott Williams & Wilkins}},
series = {{NeuroReport}},
title = {{Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector.}},
url = {{http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11924898&dopt=Abstract}},
volume = {{13}},
year = {{2002}},
}